Director - Early Assets Medical Publications, Immuno-Oncology/Oncology

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

One shared journey is moving us forward at Bristol-Myers Squibb. Around the world, we are passionate about making an impact on the lives of patients with serious disease. Empowered to apply our individual talents and ideas so that we can learn and grow together. Driven to make a difference, from innovative research to hands-on community support. Bristol-Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees the resources to pursue their goals, both at work and in their personal lives.

Key Responsibilities:

The Director, Early Oncology Medical Communications will manage a team accountable for creation of timely & relevant medical communications (publications, scientific congress presentations, core decks, Q&A documents and standard responses) to advance understanding of the science & maximize value for customers. The position, which focuses on Oncology

assets in our pipeline at various stages of preclinical and early phases of development, reports to the WW Lead, Translational Medicine and New/Early Asset Publications and Scientific Content. In this role, the incumbent is expected to:

• Create a team environment and culture which emphasizes teamwork, cooperation, personal accountability and a commitment to quality.
• Partner with Management to set goals and objectives for direct reports, working closely with medical, early clinical, and development leaders and across the Capabilities to ensure alignment.
• Manage and coach, for sustained high performance, an externally focused team accountable for developing and executing functionally and geographically integrated medical and scientific content plans; Plans and deliverables are strategically differentiating, reflect expert understanding the environment, desired educational outcomes & audience needs, and
• effectively communicates the medical value of our assets.
• Ensure plans are adjusted in accordance with clinical trial results/milestones and changes in the market healthcare landscape, monitoring the external medical and scientific information landscape and for leading internal process improvements to stay the leader in the field, and enable BMS to be viewed as the top partner of choice by healthcare professionals.
• Leverage experience and understanding of evolving landscape to consistently serve as a reliable and credible thought partner fostering collaborative relationships with academic & clinical experts, authors, publishers, medical associations & other relevant stakeholder groups.
• Work across Medical Capability and obtain to obtain critical insights ensuring development of relevant, strategic and scientifically differentiating medical communications that align with overall asset development strategy.
• Partner internally to identify, set timing and execute data dependencies and related disclosures of information through multiple communication channels for defined scope; In the case of partnerships/alliances, manages the relationship and takes accountability for the combined success.
• Effectively aligns across the matrix to drive key decisions during the medical communication development process enabling efficient issue resolution; Challenges and provides alternative perspective to increase engagement and deals effectively with resistance.
• Employ strong business acumen focused on value creation and allocates resources consistent with priorities and align own activities to adjust to project priorities; Manages the budget for defined area of responsibility demonstrating strong financial stewardship.
• Collaborate productively across matrix teams & builds credibility and represents BMS in a strong manner with external thought leaders & collaborative partners.
• Demonstrate true medical & scientific information functional subject matter expertise & credibility (e.g. CMPP certification, ISMPP active member).
• Demonstrate scientific subject matter expertise in a specific tumor type/therapeutic area/assigned scope; Ensure compliance with internal and external standards and serving as a subject matter expert on publication policies for stakeholders.
• Model BMS behaviors and holds others accountable for such behaviors at all levels in the organization.
• Display authentic leadership, change agility and enterprise mindset.

Qualifications

• Advanced scientific degree, PharmD, PhD or MD; Certification as a Medical Publication Professional (CMPP) desirable.
• 7 - 10 years of Pharma/Healthcare industry experience with an established successful track record developing and leading teams to sustained high performance.
• Experience leading Oncology medical communications across all phases (preclinical & clinical) of the drug development and commercialization process and extensive launch readiness experience.
• Demonstrated ability to drive teams to effectively manage timelines while ensuring highest quality using strong organizational, communication, facilitation and interpersonal skills working collaboratively across a matrix, multiple markets and global geographies.
• Proven ability to think strategically and take decisions even under conditions of ambiguity, evolving landscapes and tight timelines.
• Adept at building credibility with external investigators & collaborative partners, evidenced by strong leadership behaviors and excellence in the science.
• Expert knowledge of good publication practices, medical information guidance, and content standards of practice.
• Understanding of Sunshine Act, Pharma Code of Conduct, global guidance and regulations related to post-marketing practices and scientific data communication.
• Understanding of clinical trial design and execution, statistical methods, and transparency/clinical trial data reporting requirements.
• Ability to travel (domestically and internationally) 15-20% of time.